Entellus Medical (NASDAQ:ENTL) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Monday, February 5th.
A number of other equities research analysts have also issued reports on the company. William Blair lowered Entellus Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, December 8th. ValuEngine upgraded Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded Entellus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. TheStreet upgraded Entellus Medical from a “d” rating to a “c-” rating in a report on Thursday, December 14th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. Entellus Medical currently has a consensus rating of “Hold” and an average target price of $19.25.
Shares of Entellus Medical (NASDAQ ENTL) opened at $24.10 on Monday. Entellus Medical has a one year low of $11.47 and a one year high of $25.58. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.71 and a current ratio of 1.92.
Several hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co. NY acquired a new position in Entellus Medical in the 4th quarter worth about $105,000. Nationwide Fund Advisors raised its holdings in Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after purchasing an additional 2,635 shares during the period. Alliancebernstein L.P. acquired a new position in Entellus Medical in the 4th quarter worth about $224,000. JPMorgan Chase & Co. raised its holdings in Entellus Medical by 145.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after purchasing an additional 5,605 shares during the period. Finally, Chicago Capital Management LLC acquired a new position in Entellus Medical in the 4th quarter worth about $244,000. 75.67% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Entellus Medical (ENTL) Upgraded at BidaskClub” was first reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://weekherald.com/2018/02/15/entellus-medical-entl-lifted-to-sell-at-bidaskclub.html.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.